SAN MATEO, Calif., June 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX), a biopharmaceutical company focused on developing and
commercializing novel pain management therapies, announced today that it is
scheduled to present on Thursday, June 12, 2008 at the Seventh Annual
Needham & Company Biotechnology and Medical Technology Conference. Anthony
DiTonno, President and Chief Executive Officer, will be presenting at the
conference and will be available for questions.
Event: Seventh Annual Needham & Company Biotechnology and
Medical Technology Conference
Date: Thursday, June 12, 2008
Time: 3:00 p.m. ET
Place: The New York Palace Hotel, New York, NY
An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the United States Food and Drug Administration (FDA) in 2008 for PHN.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, the timing of presentations by
NeurogesX and the expected benefits of NeurogesX' potential products,
including its lead product candidate NGX-4010. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to,
NeurogesX' product candidate may have unexpected adverse side effects or
inadequate therapeutic efficacy; positive results in clinical trials may
not be sufficient to obtain FDA or European regulatory approval; physician
or patient reluctance to use NGX-4010, if approved, or the inability of
physicians to obtain sufficient reimbursement for such procedures;
potential alternative therapies; maintaining adequate patent or trade
secret protection without violating the intellectual property rights of
others; and other difficulties or delays in clinical development, obtaining
regulatory approval, market acceptance and commercialization of NGX- 4010
and the advantages of NGX-4010 over other pain therapies. For further
information regarding these and other risks related to NeurogesX' business,
investors should consult NeurogesX' filings with the Securities and
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved